Search research articles
Contact Us
Filters
Showing results (191-200 of 379) with videos related to
Page
of 38
Sort By:
Immunology
|
May 19, 2004
Selective killing of B-cell hybridomas targeting proteinase 3, Wegener's autoantigen
Katrin S Reiners, Hinrich P Hansen, Anne Krüssmann, et al.
Plos One
|
November 27, 2013
The histone deacetylase inhibitor LBH589 (panobinostat) modulates the crosstalk of lymphocytes with Hodgkin lymphoma cell lines
Jan M Klein, Alexander Henke, Maike Sauer, et al.
International Journal of Molecular Medicine
|
March 13, 2003
A novel approach for immunization, screening and characterization of selected scFv libraries using membrane fractions of tumor cells
Mehmet Kemal Tur, Achim Rothe, Michael Huhn, et al.
Haematologica
|
April 6, 2006
Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II study
Andreas Engert, Henning Bredenfeld, Hartmut Döhner, et al.
Leukemia & Lymphoma
|
April 27, 2013
Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant
Sally Arai, Michelle Fanale, Sven DeVos, et al.
Leukemia
|
October 23, 2019
Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group
Dennis A Eichenauer, Annette Plütschow, Michael Fuchs, et al.
European Journal of Haematology. Supplementum
|
July 13, 2005
Lymphocyte-predominant and classical Hodgkin's lymphoma--comparison of outcomes
Lucia Nogová, Thorsten Reineke, Andreas Josting, et al.
Blood
|
August 11, 2011
Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group
Dennis A Eichenauer, Michael Fuchs, Annette Pluetschow, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 1, 2005
Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma--a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group
Hans Theodor Eich, Uwe Haverkamp, Andreas Engert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 19, 2019
Long-Term Follow-Up of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Treated in the HD7 to HD15 Trials: A Report From the German Hodgkin Study Group
Dennis A Eichenauer, Annette Plütschow, Michael Fuchs, et al.
Page
of 38
Search research articles
Search
Showing results (191-200 of 379) with videos related to
Sort By:
Page
of 38
Immunology
|
May 19, 2004
Selective killing of B-cell hybridomas targeting proteinase 3, Wegener's autoantigen
Katrin S Reiners, Hinrich P Hansen, Anne Krüssmann, et al.
Plos One
|
November 27, 2013
The histone deacetylase inhibitor LBH589 (panobinostat) modulates the crosstalk of lymphocytes with Hodgkin lymphoma cell lines
Jan M Klein, Alexander Henke, Maike Sauer, et al.
International Journal of Molecular Medicine
|
March 13, 2003
A novel approach for immunization, screening and characterization of selected scFv libraries using membrane fractions of tumor cells
Mehmet Kemal Tur, Achim Rothe, Michael Huhn, et al.
Haematologica
|
April 6, 2006
Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II study
Andreas Engert, Henning Bredenfeld, Hartmut Döhner, et al.
Leukemia & Lymphoma
|
April 27, 2013
Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant
Sally Arai, Michelle Fanale, Sven DeVos, et al.
Leukemia
|
October 23, 2019
Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group
Dennis A Eichenauer, Annette Plütschow, Michael Fuchs, et al.
European Journal of Haematology. Supplementum
|
July 13, 2005
Lymphocyte-predominant and classical Hodgkin's lymphoma--comparison of outcomes
Lucia Nogová, Thorsten Reineke, Andreas Josting, et al.
Blood
|
August 11, 2011
Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group
Dennis A Eichenauer, Michael Fuchs, Annette Pluetschow, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 1, 2005
Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma--a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group
Hans Theodor Eich, Uwe Haverkamp, Andreas Engert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 19, 2019
Long-Term Follow-Up of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Treated in the HD7 to HD15 Trials: A Report From the German Hodgkin Study Group
Dennis A Eichenauer, Annette Plütschow, Michael Fuchs, et al.
Page
of 38